Objective To investigate the clinical efficacy of dapagliflozin combined with Entresto in the treatment of patients with valvular heart disease and heart failure and its effect on brain natriuretic peptide(BNP).Methods A total of 372 patients with valvular heart disease and heart failure who were admitted to Qinhuangdao First Hospital from March 2020 to March 2022 were enrolled as subjects and were divided into control group and study group using the simple randomization method,with 186 pa-tients in each group.The patients in the control group received Entresto alone,and those in the study group received dapagliflozin in addition to the treatment in the control group.The two groups were compared in terms of clinical outcome,serum factors,car-diac function parameters,and the incidence rate of adverse reactions.Results The study group had a significantly higher overall response rate than the control group(95.7％vs 89.2％,x2=5.561,P＜0.05).After treatment,both groups had significant reduc-tions in left ventricular end-diastolic diameter(LVEDd)and left ventricular end-systolic diameter(LVESD)and a significant in-crease in left ventricular ejection fraction(LVEF)(t=14.282-70.283,P＜0.05),and the study group had significantly better im-provements in LVEDd,LVESD,and LVEF compared with the control group(t=6.403-9.021,P＜0.05).After treatment,both groups had significant reductions in the serum levels of BNP,high-sensitivity C-reactive protein(Hs-CRP),and cardiac troponin Ⅰ(cTnⅠ)(t=19.236-69.772,P＜0.05),and compared with the control group,the study group had significantly greater reductions in serum BNP,Hs-CRP,and cTnⅠ after treatment(t=5.024-63.176,P＜0.05).The study group had a significantly lower overall incidence rate of adverse reactions than the control group(3.8％vs 9.1％,X2=4.454,P＜0.05).Conclusion Dapagliflozin com-bined with Entresto has a marked clinical effect in the treatment of patients with valvular heart disease and heart failure and can ef-fectively improve cardiac function,reduce the level of BNP,delay the progression of heart failure,and improve prognosis,with a favorable safety profile,and therefore,it holds promise for clinical application.
维普
万方数据